Shots:
- Biogen has entered into a definitive agreement to acquire Alcyone Therapeutics, building on its partnership to advance ThecaFlex DRx
- As per the deal, Biogen will acquire Alcyone Therapeutics for $85M upfront + potential milestone payments tied to the development & approval of ThecaFlex DRx with nusinersen & other products. The deal gives Biogen full rights to ThecaFlex DRx, which it plans to develop, manufacture, & commercialize. The transaction, expected to close in Q4’25, will be accounted for as an asset acquisition
- Alcyone’s remaining assets will spin off into a new company, Neela Therapeutics, backed by convertible debt financing from existing investors, including Biogen. Biogen plans to introduce Spinraza in early 2028
Ref: Biogen| Image: Alcyone Therapeutics| Press Release
Related News:- Roche to Acquire 89bio for ~$3.5B, Strengthening its CVRM Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
